Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin ReductionShuhei Suzuki, Masashi Okada, Masahiro Yamamoto et al.|Cancers|2019Cited by 42
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningiomaMasahiro Yamamoto, Chifumi Kitanaka, Tomomi Sanomachi et al.|Neuro-Oncology|2021Cited by 26
<i>In vitro</i>and<i>in vivo</i>anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profileShuhei Suzuki, Masashi Okada, Masahiro Yamamoto et al.|Oncotarget|2019Cited by 23
Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug RepurposingShuhei Suzuki, Chifumi Kitanaka, Masahiro Yamamoto et al.|Biomedicines|2020Cited by 21
Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma XenograftsMasashi Okada, Chifumi Kitanaka, Shuhei Suzuki et al.|International Journal of Molecular Sciences|2021Cited by 18